Mankind Pharma gets CCI nod for BSV acquisition

Mankind Pharma Ltd. receives regulatory approvals for 100% acquisition of Bharat Serums and Vaccines Ltd. worth ₹13,630 crore

Published - October 02, 2024 11:03 pm IST - MUMBAI

Mankind Pharma logo. File

Mankind Pharma logo. File | Photo Credit: Reuters

Mankind Pharma Ltd. said it had obtained regulatory approvals including the approval from the Competition Commission of India for 100% acquisition of Bharat Serums and Vaccines Ltd. (BSV). 

“The Proposed Transaction is subject to completion of remaining customary conditions precedent as contemplated in the Share Purchase Agreements,” the company said in a filing with exchanges.

The company hadannounced the execution of the Share Purchase Agreement dated July 25, 2024, amongst the company, BSV and the sellers Ansamira Ltd. and Miransa Ltd., (affiliates of funds managed by Advent International), and certain minority shareholders i.e. Bhaskar Iyer and Abhijit Mukherjee for the proposed acquisition of 100% stake in BSV for ₹13,630 crore.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.